Research programme: ADAPTIR multi-specific therapeutics - Aptevo Therapeutics

Drug Profile

Research programme: ADAPTIR multi-specific therapeutics - Aptevo Therapeutics

Alternative Names: Anti-CD123 x Anti-CD3; Anti-CD19 X Anti-CD-3; Anti-CD86 X mono-IL-10; Anti-HER2 X Anti-CD3; Anti-RON X Anti-CD3; APVO 210; APVO-425; APVO-436; APVO-437; CD79BxDR; CD79BxDR Scorpion™ molecule; CTLA-4 X mono-IL-10; ES-210; ES-425; ROR1 Bispecific; T-Scorp; TNFR x A2; TNFR x TWEAKR; X1 Anti-TNF-based SCORPION™; X1 TNF-based SCORPION™; X2 CTLA4-based SCORPION™

Latest Information Update: 31 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Trubion Pharmaceuticals
  • Developer Aptevo Therapeutics
  • Class Anti-inflammatories; Antineoplastics; Bispecific antibodies; Proteins; Small molecules
  • Mechanism of Action CD19 antigen inhibitors; CD3 antigen inhibitors; CD79 antigen inhibitors; CD86 antigen inhibitors; Cytotoxic T-lymphocyte antigen 4 inhibitors; ERBB 2 receptor antagonists; Glutamate carboxypeptidase II inhibitors; HLA-DR antigen inhibitors; Immunosuppressants; Receptor tyrosine kinase-like orphan receptor antagonists; RON protein inhibitors; TNFSF12 protein inhibitors; Tumour necrosis factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Graft-versus-host disease; Irritable bowel syndrome; Rheumatoid arthritis

Most Recent Events

  • 29 May 2018 Pharmacokinetics data from preclinical trials released by Aptevo Therapeutics
  • 10 May 2018 Aptevo Therapeutics plans a clinical trial of APVO 210 in 2019
  • 03 May 2018 9239335-Updated intro, kdm, FET and HE
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top